Company Analysis
Sign in

Cyclerion Therapeutics, Inc. (CYCN)

Nasdaq: CYCN · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.9
◀ Past 4.2● Present 5.3▶ Future 5.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Who owns Cyclerion Therapeutics, Inc.

As filed with the SEC
Holders of 5% or more
8
Fairmount Funds Management LLC holds 20% of Common Stock, no par value, as its SCHEDULE 13D filed Sep 11, 2026 says.
Directors and officers
15
report now, of 34 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.
Holders of 5% or moreshare of the class, as filed
Fairmount Funds Management LLC
SCHEDULE 13D · filed Sep 11, 2026 · Common Stock, no par value
20%
Peter M. Hecht
SCHEDULE 13D/A · filed Jul 20, 2026 · Common Stock, no par value · 27.9% in Mar 28, 2025
19.4%
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13D · filed Sep 15, 2026 · Common Stock, no par value per share
9.9%
Balyasny Asset Management L.P.
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock
7.33%
ADAR1 Capital Management, LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, no par value
7%
Fmr LLC
SCHEDULE 13G/A · filed Oct 7, 2026 · COMMON STOCK · 15% in May 7, 2026
6.9%
General Atlantic, L.P.
SCHEDULE 13G · filed Sep 18, 2026 · Common Stock, no par value per share
6.8%
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.
SCHEDULE 13G · filed Sep 16, 2026 · Common Stock
6.1%
American Endowment Foundation
SCHEDULE 13G/A · filed Feb 12, 2025 · Common Stock, no par value · reported falling below 5%
under 5%
Tyndall Capital Partners, L.P.
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, no par value · reported falling below 5%, from 5.1% in May 15, 2025
under 5%
J. Wood Capital Advisors LLC
SCHEDULE 13G/A · filed Oct 15, 2026 · Common Stock, no par value · reported falling below 5%, from 5.4% in Oct 17, 2025
under 5%
MFN Partners, LP
SCHEDULE 13G/A · filed Feb 12, 2025 · Common Stock, no par value · reported falling below 5%
under 5%
Slate Path Capital LP
SCHEDULE 13G/A · filed Dec 6, 2024 · Common Stock, no par value · reported falling below 5%
under 5%
What CYCN reports owning in othersstakes of 5% or more, and other ties
Cyclerion Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
19202123
2023 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.
SI Assistanton CYCN · research, not advice